Items where Author is "Solaro, C."

Article

(2025) Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA neurology. ISSN 2168-6157 (Electronic) 2168-6149 (Print) 2168-6149 (Linking)

(2024) Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. Journal of Medical Economics. pp. 109-125. ISSN 1369-6998

(2024) Disease Activity in Pregnant and Postpartum Women with Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation. ISSN 23327812 (ISSN)

(2023) Comparative effectiveness in multiple sclerosis: A methodological comparison. Multiple Sclerosis Journal. pp. 326-332. ISSN 1352-4585

(2023) Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 875-883. ISSN 1352-4585

(2023) Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. Journal of Neurology Neurosurgery and Psychiatry. pp. 1004-1011. ISSN 0022-3050

(2023) Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology. pp. 1014-1024. ISSN 1351-5101

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. pp. 2321-2334. ISSN 1351-5101 1468-1331 J9 - EUR J NEUROL

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology. pp. 2321-2334. ISSN 13515101 (ISSN)

(2021) Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Comput Methods Programs Biomed. p. 106180. ISSN 0169-2607

(2021) The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. Mult Scler Relat Disord. p. 103012. ISSN 2211-0348

(2019) Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. Jama-Journal of the American Medical Association. pp. 175-187. ISSN 0098-7484

(2019) Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. pp. 458-468. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2018) Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurol. pp. 1407-1415. ISSN 2168-6157 (Electronic) 2168-6149 (Linking)

(2017) Contribution of inflammation to disability accrual in primary progressive multiple sclerosis. Multiple Sclerosis Journal. pp. 399-401. ISSN 1352-4585

(2017) Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 71-73. ISSN 1352-4585

(2017) The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis. Multiple Sclerosis Journal. pp. 32-34. ISSN 1352-4585